Estrogen / cMyc Cancer Research Results

Est, Estrogen: Click to Expand ⟱

Features:

Estrogen is a hormone that plays a crucial role in the development and progression of various types of cancer. (ER-positive cancers).
ER-positive cancers tend to have a better prognosis than ER-negative cancers, as they are more likely to respond to hormone therapy.

Negative effects of estrogen supplements on cancer:
Breast cancer: Estrogen supplements can increase the risk of breast cancer, particularly in postmenopausal women. This is because estrogen can stimulate the growth of estrogen receptor-positive (ER+) breast cancer cells.
Endometrial cancer: Estrogen supplements can increase the risk of endometrial cancer, particularly in women who have not had a hysterectomy. This is because estrogen can stimulate the growth of endometrial cells, leading to an increased risk of cancer.
Ovarian cancer: Some studies suggest that estrogen supplements may increase the risk of ovarian cancer, although the evidence is not conclusive.

Positive effects of estrogen supplements on cancer:
Colorectal cancer: Some studies suggest that estrogen supplements may reduce the risk of colorectal cancer, particularly in postmenopausal women.
Prostate cancer: Estrogen supplements may have a protective effect on prostate cancer, although the evidence is not conclusive.

cMyc, cellular-MYC oncogene: Click to Expand ⟱

Source:

Type: oncogene

The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.

Scientific Papers found: Click to Expand⟱

975-

Est,

Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism

vitro+vivo,

UEC,

GLS↑, cMyc↑, GlutMet↑, tumCV↑, TumAuto↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Core Metabolism/Glycolysis ⓘ

cMyc↑, 1, GLS↑, 1, GlutMet↑, 1,

Transcription & Epigenetics ⓘ

tumCV↑, 1,

Autophagy & Lysosomes ⓘ

TumAuto↓, 1,
Total Targets: 5

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells